Having observed the reduction in dormancy following SMO inhibition, we investigated whether PF-04449913 sensitized BC LSC to dasatinib (Figure 5a) - a potent BCR-ABL TKI that targets dividing cells. This evidence concerns the gene ABL1 and breast cancer.